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Background: Acute Coronary Syndrome (ACS) is a leading cause of morbidity and mortality.
Perturbed gut- microbiota (dysbiosis) and increased intestinal permeability (leaky-gut) with
translocation of bacterial antigens, play critical role in obesity and metabolic syndrome, which
are also major ACS risk factors. Additionally, Trimethylamine-N-Oxide (TMAO), a metabolite
produced by phylum Proteobacteria in gut is implicated in developing ACS. As Proteobacteria
is a major source of translocated antigen lipopolysaccharides (LPS), we hypothesized that ACS
patients have leaky-gut condition characterized by dysbiosis with increased Proteobacteria, leading
to elevated blood levels of TMAO and LPS.
Methods: In a pilot case-control study, we enrolled 19 ACS patients (within 72-h of cardiac
events) and 19 healthy-controls. Gut barrier function was determined using lactulose-to-mannitol
urinary excretion ratio (L/M ratio). Stool microbiome composition was examined using16S
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sequencing and predictive functional analysis for LPS biosynthesis pathway by PICRUSt tool.
Serum TMAO and LPS levels were measured.
Results: ACS patients had increased Gammaproteobacteria compared to controls:1.8 ±3.0 vs. 0.2
±0.4% (P =0.04). Though Proteobacteria level was increased but not statistically significant: 4.1
±3.8 vs. 2.1 ±1.7% (P =0.056). L/M-ratio was three times higher in ACS patients; 0.06 ±0.07 vs
0.023 ±0.02, (P =0.014). Surprisingly, there was no difference in the mean serum LPS or TMAO
levels. However, PICRUSt analysis indicated increased Proteobacteria population increasingly
contributed to LPS biosynthesis in ACS patients only.
Conclusions: ACS patients likely to have leaky-gut and perturbed gut microbiota. Further
studies are required to precisely define the role of dysbiosis in ACS.
Keywords
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1.

Introduction

Author Manuscript

Acute Coronary Syndrome, (ACS; aka heart attack) is a leading cause of morbidity and
mortality. Despite decades of research, our understanding of ACS pathophysiology is
still obscure, especially in the context of the gut-microbiome. The gut-microbiome is
increasingly recognized as a ‘super organ’ that serves plethora of important host functions
such as metabolism and immune homeostasis [1]. These functions are attributed to bacterial
genomic content of gut-microbiome which outnumbers our own genomic content by about
150 times [2]. Therefore, it is not surprising that alterations in the intestinal microbiome aka
‘dysbiosis’ are associated with various disease conditions, including metabolic syndrome,
atherosclerosis and obesity; conditions which are also major ACS risk factors [3].
The gut dysbiosis is associated with increased intestinal permeability ‘aka leaky gut’
[4]. Leaky gut is implicated in cardiovascular complications [5] besides, pathophysiology
of Celiac disease, Inflammatory Bowel Disease (IBD) [6]. Furthermore, translocation of
luminal antigens to the systemic circulation (with underlying leaky gut) has also been
postulated to be an important pathogenic factor in non-alcoholic fatty liver disease, obesity,
Type 2 diabetes, and metabolic syndrome, all of which are also known risk factors for ACS
[7,8].

Author Manuscript

The outer membrane of Gram-negative bacteria consists of lipopolysaccharides (LPS) aka
endotoxins. The elevated level of endotoxin in systemic circulation is associated with
a threefold increased risk of developing atherosclerosis [9]. Endotoxins bind Toll-Like
Receptor-4 (TLR-4) present on the intestinal, immune and endothelial cells, and form a
TLR-4 receptor cluster with the Cluster of Differentiation-14 (CD14). TLR4 polymorphism
confers reduced risk of atherosclerosis [10], while CD14 promoter polymorphism leads to an
increased risk of ACS and atheromatous plaque vulnerability [11]. The possible mechanism
include endotoxin-induced damage to the endothelial cells which stimulates macrophage
transformation into foam cells promoting atherosclerosis [12]. Studies from our lab have
shown that endotoxin – at clinically achievable concentration cause an increase in intestinal
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permeability both in vitro and in vivo models [13]. The increase in serum endotoxin levels
causes a further increase in intestinal permeability which in turn allows surge of endotoxins,
culminating in an amplification cascade of increase in intestinal permeability and worsening
endotoxemia.

Author Manuscript

Very few studies have described the link between gut-microbiome and atherosclerosis or
ACS. In one such interesting study, Proteobacteria were found within the endarterectomy
samples of atherosclerotic plaques [14] and further presence of Proteobacteria in blood was
associated with an increased risk of cardiac events (Odds ratio 1.56, 95%CI 1.12–2.15)
[15]. A well described link between the intestinal microbiome and ACS is the metabolite
trimethylamine-N-Oxide (TMAO). The dietary phospholipids, such as phosphatidylcholine
and L-carnitine are metabolized by intestinal bacteria to yield trimethylamine (TMA) that is
subsequently absorbed and metabolized into TMAO in the liver [16]. Multiple studies have
revealed an association between TMAO and risk for cardiovascular events [16,17].
Proteobacteria is a primary source of TMAO and endotoxemia, which are risk factors for
atherosclerosis and future ACS events [18]. Therefore, we hypothesized that ACS patients
have leaky-gut condition characterized by an increased Proteobacteria (dysbiosis), which
leads to higher levels of blood TMAO and LPS. Goal of our study was to investigate
(immediately after an acute cardiac event) whether patients with ACS have underlying
dysbiosis, increased intestinal permeability, and higher levels of serum endotoxins and
TMAO.

2.
2.1.

Methods
Study design overview

Author Manuscript

This is a pilot case-control study performed in a single tertiary center; University of New
Mexico Hospital, between March 2014 and November 2016. For detailed materials and
methods please refer to Supplementary methods section.
2.2.

Inclusion criteria

Author Manuscript

Patients admitted with a diagnosis of ACS. The definition of ACS as described by
the American Heart Association was used, including ST-elevation myocardial infarction
(STEMI) and non-ST segment elevation myocardial infarction (NSTEMI). All patients were
recruited in the study within 72 h of admission. Healthy controls (matched to cases by age
and sex) met the following criteria: have normal body mass index (18.5 < BMI < 24.9), no
hypertension, diabetes or dyslipidemia, no prior heart attacks or strokes, no tobacco use, and
no antibiotic use within three months prior to enrollment. Controls were recruited through
the University of New Mexico Clinical and Translational Science Center (CTSC) registry of
healthy controls.
2.3.

Exclusion criteria
Patients less than 19 years, pregnancy, abnormal kidney function, heart failure, intensive
care unit (ICU) level of care.
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Sample size
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was calculated to achieve a statistical power >80%, and a level of significance α = 0.05. To
detect a 100% increase in intestinal permeability in the ACS group compared to the control
group; 17 patients per groups were required (effect size based on prior work in our lab).
Therefore, we enrolled 19 subjects in each healthy and control group.
2.5.

Measuring barrier functions

Author Manuscript

Intestinal permeability was measured using mannitol (M) and lactulose (L) urinary
excretion method. L/M ratio is a well-validated marker for intestinal permeability [19].
The concentration of mannitol and lactulose present in the urine was determined by
an enzyme-based assay (Megazyme, Ireland) and quantified by spectrophotometry. The
lactulose-to-mannitol ratio (L/M ratio) was calculated by dividing the fractional (percentage)
of urinary excretion of lactulose over the fractional excretion of mannitol.
2.6.

Quantifying serum TMAO levels
Serum TMAO was measured using a highly sensitive liquid chromatography electrospray
ionization mass spectrometry (LCMS), performed at Cleveland HeartLab, Inc. (Cleveland,
OH, USA).

2.7.

Determining serum LPS levels
LPS serum level was measured using a Limulus amebocyte lysate (LAL) chromogenic
endotoxin quantification kit (Thermo Scientific, IL, USA).

2.8.

DNA extraction
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DNA extraction from stool samples was performed using the ZR Fungal/Bacterial Miniprep
Kit (Zymo Research, CA, USA).
2.9.

MetaVx™ mammalian library preparation and Illumina MiSeq sequencing
Next generation sequencing library preparations and Illumina MiSeq sequencing were
conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA). Please refer to Supplementary
methods section.

2.10.

Sequence analysis by QIIME pipeline
Please refer to Supplementary methods section.

2.11.

Predicting functional content from 16S gene
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Please refer to Supplementary methods section.
2.12.

Statistical tests
Standard unpaired t-test (two-tailed) was used for data with normal distribution, and nonparametric t-test (Satterthwaite and Mann-Whitney-Wilcoxon) were used for data with
unequal variance, or data that are not normally distributed.
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Results
Subject characteristics
19 ACS patients and 19 healthy controls were recruited. More than two thirds of ACS
patients as well as healthy controls were Caucasian (non-Hispanic Whites) males, patients
were in their mid-fifties as expected for the first ACS episode, and were slightly older than
the healthy controls. ACS patients were overweight (mean BMI of 28.3); a 4-point higher
BMI than healthy controls. All ACS patients underwent urgent coronary angiography;
eighty-nine percent had STEMI. The mean troponin level was markedly elevated at 30.07
ng/mL, while 63% patients had a single vessel disease. Complete characteristics of patients
and healthy controls are described in Table 1.

3.2.

Increased intestinal permeability in ACS patients

Author Manuscript

The absorption of mannitol and lactulose are used to assess overall mucosal absorptive
surface area and also paracellular permeability, respectively, such that mucosal cell damage
and reduced surface area are associated with decreased mannitol absorption while increased
intestinal tight-junctional permeability (leaky gut) correlates with an increased lactulose
absorption. The lactulose-to-mannitol ratio (L/M ratio) was calculated by dividing the
fractional (percentage) of urinary excretion of lactulose over the fractional excretion of
mannitol. Fifty percent of patients (n = 8) and most controls (n = 16) completed the L/M
permeability test. ACS patients had leaky gut as evidenced by the L/M ratio that was three
times higher than the healthy controls (P = 0.014) (Fig. 1A and B).
3.3.

Healthy and ACS subjects had similar blood TMAO and LPS levels

Author Manuscript

We expected ACS group to show significantly higher levels of TMAO but surprisingly, all
subjects had similar serum TMAO concentrations. Mean TMAO levels for ACS and healthy
groups were 5.8 μM ± 4.8 vs 5 ± 2.9 (P = 0.5) respectively, (Fig. 1C). Further, when the
mean serum LPS level was measured by LAL chromogenic assay, there was a trend towards
a higher LPS levels in the ACS group but not statistical significant (P = 0.3) (Fig. 1D).
3.4.

Microbiome analysis overview

Author Manuscript

Alpha Diversity: We sequenced all samples to detect all available OTUs as shown in the
observed-OTUs rarefaction plot (Fig. 2A). In both groups the number of observed OTUs
(mean +/−SD) was more than 1000 (1928.9 ± 1165.1 vs. 1336.2 ± 611.7, P-value = 0.19).
Phylogenic Diversity (PD): is an indicator of biodiversity, PD was measured for all samples
(Fig. 2B). Our results showed no significant difference in PD between the two groups: mean
PD (+/−SD) in ACS patients vs healthy controls was 111.63 ± 45.65 vs. 86.55 ± 25.69,
P-value = 0.16. Chao1 Index: a measure of sample richness was performed for all subjects
(Fig. 2C). The Chao1 index was similar in ACS patients and healthy controls: mean Chao1
index was 3303.3 ± 1747.6 vs. 2415.8 ± 977.7, P-value = 0.2 (Fig. 2D). Beta diversity:
Unique Fraction Distance (Unifrac) distance (weighted for abundance) was uniform; a mean
distance of ∼0.4 was noted between samples within the same group and between samples
within different groups (Fig. 2E). Principal Component Analysis (PCoA): of Unifrac
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distance showed similar distribution of ACS and healthy subjects along the three PCA axes;
no distinct group clustering was observed (Fig. 2F).
3.5.

Major bacterial phyla in both groups
16S rRNA analysis revealed the relative abundance of intestinal major bacterial phyla in
both groups (Fig. 3A) and in individual subjects (Fig. 3B). Both groups had Bacteroidetes
and Firmicutes as the two major phyla, and a small percentage of Proteobacteria and
Actinobacteria. Although the mean Proteobacteria percentage was double in ACS patients
compared to controls (4.1 ± 3.8 vs 2.1 ± 1.7), the result was not statistically significant
(P-value = 0.056) (Fig. 3C). There was also no significant difference in Bacteroidetes,
Firmicutes, and Actinobacteria relative abundance between the two groups (Fig. 3(D–F)).

3.6.

Dysbiosis with increased relative abundance of Gammaproteobacteria in ACS

Author Manuscript

Lower taxonomical levels in Phylum Proteobacteria reveals the relative abundances of
Gammaproteobacteria (Class) and Enterobacteriaceae (Family) were higher in ACS patients
compared to controls. Relative abundance values were statistically significant at the
Gammaproteobacteria level (Fig. 4(A–C)). Relative abundance of different bacterial OTUs
was calculated by group and in individual subjects (Fig. 4D and E). More than twenty
bacterial genera/families had more than 2-fold difference between the two groups (Fig. 4F).
ACS patients had higher levels of Prevotella and controls had higher overall Bacteroidales
levels. Elevated Prevotella/Bacteroides (B/P ratio) is a microbiome enterotype linked to
carbohydrate rich diet and cardiovascular risk such as hypertension (HTN) [20].
3.7. Functional analysis revealed microbiome source contributing LPS biosynthesis
markedly increased in ACS patients

Author Manuscript

A predictive functional analysis of LPS biosynthesis showed a marked difference in the
phyla contributing LPS biosynthesis. In ACS patients, the main source of LPS biosynthesis
pathways was Proteobacteria, compared to Bacteroidetes in the healthy controls group (Fig.
4G). 16S rRNA sequencing analysis showed no increased abundance of any specific taxon
capable of producing LPS.
All major results for both groups are summarized in Supplementary Table S1.

4.

Discussion

Author Manuscript

We found that ACS patients have increased intestinal tight-junctional permeability (leaky
gut); the lactulose-to-mannitol urinary excretion ratio was three times higher in patients
compared to controls; 0.06 ± 0.07 vs 0.02 ± 0.02 (P = 0.014). There was no significant
difference in the levels of TMAO and LPS between the two groups. However, functional
analysis revealed that LPS biosynthetic pathway in ACS patients is mainly comprised of
Proteobacteria as opposed to Bacteroidetes in healthy controls. (Fig. 4G).
Additionally, ACS patients have nine-fold increase in intestinal Gammaproteobacteria (a
Class that includes opportunistic pathogenic Gram-negative bacteria), compared to healthy
controls. Proteobacteria level was 2-folds higher in ACS patients, with no statistical
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significance (P = 0.056). The Proteobacteria (facultative anaerobes) level detected in
stool samples (luminal fraction) is expected to be lower than what is actually present
on the mucosal surface of distal intestine (mucosa-associated fraction) [21], suggesting
that ACS patient’s mucosal surface might have significantly higher relative abundance
of Proteobacteria. ACS patient fecal samples clearly suggest some degree of dysbiosis
compared to healthy controls, following an acute cardiac event.
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Intestinal Proteobacteria is the most unstable of the four-major intestinal bacterial
phyla [Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria] [22]. High levels of
Proteobacteria is a key feature of dysbiosis in many inflammatory and metabolic conditions
such as metabolic syndrome, obesity, diabetes mellitus and inflammatory bowel disease
[23,24]. A recent study on atherosclerotic cardiovascular disease (218 patients) showed
increased Enterobacteriaceae (a major Family within the Class Gammaproteobacteria)
compared to controls [25].
Previous studies have confirmed a strong correlations between dysbiosis with higher levels
of endotoxins/TMAO and development of a future cardiovascular event, but such studies are
scarce for patients during acute cardiac events. With the limited number of ACS subject’s
sample analysis, we showed an increase in Gammaproteobacteria in ACS patients and an
increase in intestinal permeability, however, increased LPS levels were not observed.

Author Manuscript

Gram-negative bacteria produce different endotoxins—with major variation in the
immunogenic Lipid A portion—that bind to TLR4. Endotoxins (with different lipid A)
activate innate immune system and trigger a largely variable immunogenic response [26–
28] – leading to a range of disease conditions. For example, LPS from Proteobacteria
is structurally distinct from Bacteroides LPS, and Proteobacteria LPS is markedly more
immunogenic [26,27]. Although LPS levels were not different between the two groups in
this study, it is possible that ACS patients have higher immunogenic Proteobacteria-LPS
based on our functional analysis, this can only be confirmed with analyzing different types
of serum LPS, which is beyond the scope of present study.

Author Manuscript

We found no difference in TMAO levels between the two groups, this result is consistent
with a recent study in patients with acute stroke and Transient Ischemic Attacks (TIAs) [29];
wherein patients had lower levels of TMAO compared to controls. This doesn’t contradict
the previous large studies where high levels of TMAO correlated with increased risk of
future acute cardiac events. It is likely that TMAO level is associated with a long-term risk
of cardiovascular events and level at the time of the ACS event can be normal or low. In
addition, TMAO levels are known to fluctuate widely over the course of time (R2 = 0.29, P
= 0.003) [30].

5.

Limitations
Only 50% of ACS patients underwent the intestinal permeability test due to delayed IRB
approval, leading to a smaller than planned sample size. Intestinal permeability was three
times higher in ACS patients compared to controls (large effect size) and therefore result
was statistically significant. ACS patients had higher BMI compared to healthy controls

Hum Microb J. Author manuscript; available in PMC 2022 May 02.

Alhmoud et al.

Page 8

Author Manuscript

(mean BMI of ACS patients is 28.31 ± 1.9 vs 24.3 ± 0.39 for healthy controls). Elevated
BMI can alter the intestinal microbiome and affect the study results, we reanalyzed the study
endpoints including ACS patients who have normal BMI (BMI less than 25) compared to
healthy controls. Our results still show difference between the two groups after we correct
for the BMI variable (Supplementary Table S2).

6.

Future directions

Author Manuscript

To establish a clear association among ACS, leaky-gut and gut microbiota, a larger scale
exploratory study is required. Recruiting a significantly larger number of patients to
investigate detailed changes at the bacterial strain level (which we propose doing using a full
metagenomics and metatranscriptomics approach) will add greater insight on the potential
function of the microbiome and interactions with the host. Outcome of such studies will
open the door for interventional studies targeting the microbiome composition and function
using probiotics and prebiotics to alter enzymatic pathways affecting TMAO metabolism,
tightening the intestinal TJ, and balancing the microbiome composition.

7.

Conclusions
Dysbiosis affects patients with ACS, with an increase in intestinal permeability. It is unclear
if dysbiosis and leaky gut are mere associations, or key contributing factors in acute cardiac
events hence, large scale exploratory studies are required to find the exact role of dysbiosis
in ACS patients.

Supplementary Material
Author Manuscript

Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Lactulose to mannitol (L/M) ratio, trimethyamineoxide (TMAO) and lipopolysaccharide
(LPS) levels. (A–B) L/M ratio in ACS patients and healthy controls, and mean L/M ratio in
both groups. (C) TMAO serum levels in ACS patients and healthy controls. (D) LPS serum
levels in ACS patients compared to healthy controls. *Healthy controls. **Acute coronary
syndrome. ***Lactulose to mannitol ratio.
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Fig. 2.
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Diversity of the intestinal microbiome in ACS patients and healthy controls. (A–C)
Rarefaction plots showing number of OTUs, phylogenetic diversity and Chao1 index
for individual subjects. (D) Chao1 index per group. (E) Weighted unique fraction
group distances. (F) Principal component analysis of weighted unique fraction distance.
*Operational taxonomic unit. ** Principal component analysis.
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Fig. 3.

Relative abundance of major bacterial phyla in ACS patients and healthy controls. (A)
Relative abundance of bacterial phyla per group. (B) Relative abundance of bacterial
phyla per subject. (C–F) Levels of fecal Proteobacteria, Bacteroidetes, Firmicutes, and
Actinobacteria in ACS patients compared to healthy controls. *Acute coronary syndrome.
**Healthy controls.
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Fig. 4.

Relative abundance of Gammaproteobacteria, Enterobacteriaceae and other bacterial genera
in study subjects. (A–B) Levels of fecal Gammaproteobacteria and Enterobacteriaceae
in ACS patients compared to healthy controls. (C) Summary of Proteobacteria,
Gammaproteobacteria and Enterobacteriaceae levels per group. (D, E) Relative abundance
of bacteria per group and per subject at the genus level, for legend refer to Supplementary
Fig. 1 (S1 Figure). (F) Bacterial genera with more than 2-fold difference between the two
groups. Red color indicates higher abundance. (G) Bacterial phyla contribution to LPS
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synthesis in ACS patients and healthy controls. *Acute coronary syndrome. **Healthy
controls.
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Baseline characteristics of ACS patients and healthy controls.
Baseline characteristics

ACS group (n =19)

Control group (n =19)

P-value

Age (mean ±SD*)

54.4 ±2.2

49 ±1.6

0.07

Gender, Male (n, %)

14 (74)

13 (68)

0.7

28.31 ±1.9

24.3 ±0.39

0.004

Caucasian

13 (68)

14 (74)

0.72

Others

6 (32)

5 (26)

Clinical characteristics

n (%)

n (%)

Alcohol use

7 (37)

0 (0)

-

Current smoker

4 (21)

0 (0)

-

Ex-smoker

4 (21)

0 (0)

-

Non-smoker

11 (58)

0 (0)

-

Family history of CAD**

13 (68)

0 (0)

-

Diabetes Mellitus Type II

4 (21)

0 (0)

-

Hypertension

6 (32)

0 (0)

-

‡
Prior ACS

2 (10)

0 (0)

-

NA

NA

BMI

(kg/m2)

(mean ±SD)

Race

Tobacco use

Author Manuscript

Past Medical History

Admission diagnoses

§

17 (89)

STEMI

II

2 (10)

NSTEMI

Intervention

Author Manuscript

Coronary angiography with PCI

¶

Stent placement

19 (100)
18 (95)

Number of affected vessels
One-vessel disease

12 (63)

Two-vessel disease

6 (32)

Three-vessel disease

1 (5)

Mean Troponin level

30.07 ng/mL

*

Standard deviation.

**

Coronary artery disease.

‡

Acute coronary syndrome.
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§

ST-segment elevation myocardial infarction

II

Non-ST segment myocardial infarction.

¶

Percutaneous coronary intervention.
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